Dr. Ip Ho Wan - Pathology
Specialist in Pathology
Highlights
- MCHK RegisteredVerified
- Specialist in PathologyBachelor of Medicine and Bachelor of Surgery (MBBS) · The Hong Kong College of Pathologists · Medical degree 2008
- InsuranceBeing compiled｜See details
About
Dr. Ip Ho Wan is a registered Pathology specialist in Hong Kong.
Education
Specialist in Pathology
- Bachelor of Medicine and Bachelor of Surgery (MBBS)Bachelor of Medicine and Bachelor of Surgery (MBBS)2008
Hong Kong Academy of Medicine fellowships
- FHKCPathFellow, The Hong Kong College of Pathologists
Source: Hong Kong Academy of Medicine Fellows Register, checked 12 Sep 2026
Insurance
Insurance plans being compiled
We're collecting insurance plan data per clinic. For confirmation, contact the clinic directly.
Are you Dr. Ip Ho Wan? Claim page and update insurance →
FAQ
Is Dr. Ip Ho Wan any good?
Dr. Ip Ho Wan is a registered Pathology specialist in Hong Kong. Qualifications and registration come from the Hong Kong Medical Council. ok.med does not rate or rank doctors.
What does Dr. Ip Ho Wan do?
Dr. Ip Ho Wan practises in Pathology.
Are you Dr. Ip Ho Wan? Claim this page to update and manage.
ClaimResearch and publications
10 papers
Filter by paper topic
Topics come from medical classifications on these PubMed papers, not from the doctor's listed services.
- Mechanism of Initial Favorable Response to Decitabine in TP53-Mutated MDS/AML and Potential Mechanisms of Subsequent Relapse.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
- Sorafenib and omacetaxine mepesuccinate as a safe and effective treatment for acute myeloid leukemia carrying internal tandem duplication of Fms-like tyrosine kinase 3.Cancer · 2020
- Myeloproliferative neoplasms treated with hydroxyurea, pegylated interferon alpha-2A or ruxolitinib: clinicohematologic responses, quality-of-life changes and safety in the real-world setting.Hematology (Amsterdam, Netherlands) · 2020
- Clofarabine, cytarabine, and mitoxantrone in refractory/relapsed acute myeloid leukemia: High response rates and effective bridge to allogeneic hematopoietic stem cell transplantation.Cancer medicine · 2020
- Oral arsenic trioxide incorporation into frontline treatment with all-trans retinoic acid and chemotherapy in newly diagnosed acute promyelocytic leukemia: A 5-year prospective study.Cancer · 2019
- Next-generation sequencing with a 54-gene panel identified unique mutational profile and prognostic markers in Chinese patients with myelofibrosis.Annals of hematology · 2019
- Long-term outcome of relapsed acute promyelocytic leukemia treated with oral arsenic trioxide-based reinduction and maintenance regimens: A 15-year prospective study.Cancer · 2018
- Homoharringtonine (omacetaxine mepesuccinate) as an adjunct for FLT3-ITD acute myeloid leukemia.Science translational medicine · 2016
- Dysregulation of the intrinsic apoptotic pathway mediates megakaryocytic hyperplasia in myeloproliferative neoplasms.Journal of clinical pathology · 2016
- Diagnosis and prevention of thalassemia.Critical reviews in clinical laboratory sciences · 2013
Publication data comes from PubMed / Europe PMC and is matched automatically by name and affiliation. Every entry links to the source.
For reference only. Not medical advice. Read full disclaimer